CLDN6

BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR

Retrieved on: 
星期一, 四月 11, 2022
Company, Private Securities Litigation Reform Act, Immunotherapy, CLDN6, Clinical trial, Netherlands Cancer Institute, Sarcoma, CAR, SEC, BioNTech, Program, Neoplasm, Fallopian tube cancer, Cancer, RNA, Deepening, Entrepreneurship, Regeneron Pharmaceuticals, Ovarian cancer, NKI, Hoffmann-La Roche, Endometrial cancer, Safety, Review, Hematological Cancer Research Investment and Education Act, RNA transfection, Stomach, Nasdaq, Geneve L. A. Shaffer, GLOBE, Toxic shock syndrome, Testicular cancer, BNTX, Nature, Annual report, Patient, Infection, Vaccine, Medical imaging, Pharmaceutical industry, Genentech, Pfizer

The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211.

Key Points: 
  • The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211.
  • The data were presented in the Clinical Trials Plenary Session at the AACR Annual Meeting 2022 by Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
  • Tumor indications included testicular cancer (n=8) ovarian cancer (n=4), endometrial cancer, fallopian tube cancer, sarcoma, and gastric cancer (1 patient each).
  • Our preliminary data indicate that the successes of CAR-T in hematological cancers may indeed be transferred to solid tumors.

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Retrieved on: 
星期三, 三月 23, 2022
Company, Private Securities Litigation Reform Act, Therapy, Cancer, Sale, Ovary, Forward-looking statement, Immunotherapy, CLDN6, IND, Breast, AACR, Research, Biotechnology, Program, ER, American Association, CEO, MBC, SVP, 2021 Essex County Council election, G&A, Association, Endometrial cancer, Intention, PR, Nasdaq, Monoclonal antibody, U.S. Securities and Exchange Commission, GLOBE, Income, VP, R, IPO, Breast cancer, Insurance, Context, Patient, Pharmaceutical industry, Medical imaging

PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced financial results for the year ended December 31, 2021, and highlighted recent corporate accomplishments.

Key Points: 
  • PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers,today announced financial results for the year ended December 31, 2021, and highlighted recent corporate accomplishments.
  • Context has bolstered our corporate, financial, and scientific efforts over the past two quarters.
  • ET, Context will host an investor R&D webinar with the Companys management team and AACR presenters to discuss the results from these presentations.
  • Context reported a net loss of $10.5 million for 2021, as compared to net income of $6.6 million for the same period in 2020.

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期三, 三月 9, 2022
Safety, GMP, Twitter, Form 20-F, Annual report, Private Securities Litigation Reform Act, Risk, Company, CLDN6, Antibody, Immune system, U.S. Securities and Exchange Commission, Cancer, Lishui, NDA, Degenerative disease, Intellectual property, CD45, CD8, Toxicity, Patient, WeChat, Enoblituzumab, Neoplasm, Technology, COVID-19, B7, Liver, B7-H3, FC, LinkedIn, Vaccine, Pharmaceutical industry

Taken together, these data support further development of TJ-C64B towards clinical development subsequently.

Key Points: 
  • Taken together, these data support further development of TJ-C64B towards clinical development subsequently.
  • Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of immune regulator proteins.
  • B7-H3 is widely expressed by many different tumor types and may play a key role in regulating the immune response to various types of cancer.
  • TJ-C64B is a bispecific antibody simultaneously targeting tumor associated antigen Claudin 6 (CLDN6) and costimulatory molecule 4-1BB for CLDN6+ tumor treatment.

Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

Retrieved on: 
星期四, 十二月 2, 2021
Path integral molecular dynamics, Private Securities Litigation Reform Act, Patient, Research, Sale, CEO, Bispecific monoclonal antibody, Cancer, ER, Forward-looking statement, Company, Exercise, Woman, Jennifer, Context, IPO, Breast, PR, Breast cancer, CLDN6, Nasdaq, R, Oncology nursing, GLOBE, U.S. Securities and Exchange Commission, Fulvestrant, G&A, Immunotherapy, Therapy, Intention, Abstract, Vii, Window, Territory, Pharmaceutical industry, Security (finance)

PHILADELPHIA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments.

Key Points: 
  • PHILADELPHIA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a womens oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers,today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments.
  • In November 2021, announced the appointment of Jennifer Minai-Azary as Chief Financial Officer and the prior appointment, in April 2021, of Alex Levit as Chief Legal Officer.
  • Context reported a net loss of $1.4 million for the third quarter of 2021, as compared to a net loss of $0.9 million for the same period in 2020.
  • Context Therapeutics Inc. (Nasdaq: CNTX), is a womens oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers.

BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting

Retrieved on: 
星期一, 十一月 1, 2021
Safety, CLDN6, RNA transfection, Immunotherapy, Entrepreneurship, Cancer, Elanco, Hoffmann-La Roche, BNTX, Patient, Society, Infection, Company, Regeneron Pharmaceuticals, BioNTech, Nasdaq, GLOBE, Geneve L. A. Shaffer, SITC, Pharmaceutical industry, Vaccine

The presentation is scheduled for the late-breaking abstract poster session at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021.

Key Points: 
  • The presentation is scheduled for the late-breaking abstract poster session at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021.
  • Claudin-6 is a new target that we believe is well-suited for CAR-T therapy and presents a differentiated avenue for the treatment of solid tumors.
  • BNT211 is an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin 6 (CLDN6) and the first CAR-T product candidate in the Companys clinical development.
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.